VXRT - アビラジェン・セラピュ―ティクス (Vaxart Inc.) アビラジェン・セラピュ―ティクス

 VXRTのチャート


 VXRTの企業情報

symbol VXRT
会社名 Vaxart Inc (アビラジェン・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 バクサルト(Vaxart Inc.)(旧名:Aviragen Therapeutics Inc.)は感染症を治療するための直接作用型抗ウイルス薬の発見・開発に従事する。同社は治療の選択肢が限られるウイルス感染症に対処する臨床開発中の3種類の候補製品を有する。製品は第IIb相の酒精試験で評価されるヒト・ライノウイルス(HRV)感染症の中・重度の喘息患者のための経口治療薬のvapendavir、呼吸器合胞体ウイルス(RSV)感染の治療・予防のための第Ⅱ相開発における経口融合(F)タンパク質阻害剤であるBTA585、ヒトパピローマウイルス6型および11型に起因するコンジロームの第II相開発における局所抗ウィルス治療薬であるBTA074を含む。同社は前臨床RSV非融合阻害剤プログラムを有する。同社は感染症を予防・治療できる小分子化合物の発見と開発に研究と薬剤開発キャパシティを集中する。  アビラジェン・セラピュ―ティクスは米国のバイオ医薬品企業。呼吸関連のウイルス感染に対応する経口・小分子化合物に焦点を当て、インフルエンザの治療向けリレンザ(グラクソスミスクラインより販売)やイナビル(第一三共製薬より販売)を開発したほか、鼻炎の原因であるライノウイルスや、呼吸系発疹ウイルスの治療薬の開発にも従事。本社はジョ―ジア州。   Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines. Its products include Influenza, Norovirus and Respiratory Syncytial Virus. The company was founded in 2004 and is headquartered in South San Francisco, CA.
本社所在地 290 Utah Ave. Suite 200 South San Francisco CA 94080 USA
代表者氏名 Wouter Latour ワウターラトゥール
代表者役職名 President Chief Executive Officer Director 社長兼最高経営責任者(CEO)
電話番号 +1 650-550-3500
設立年月日 25263
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 16人
url www.aviragentherapeutics.com
nasdaq_url https://www.nasdaq.com/symbol/vxrt
adr_tso
EBITDA EBITDA(百万ドル) -9.26800
終値(lastsale) 4.88
時価総額(marketcap) 34849002.32
時価総額 時価総額(百万ドル) 26.80374
売上高 売上高(百万ドル) 2.95000
企業価値(EV) 企業価値(EV)(百万ドル) 7.39874
当期純利益 当期純利益(百万ドル) -9.05600
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Vaxart Inc revenues totaled $2.1M. Net loss applicable to common stockholders totaled to $6.9M. Results are not comparable due to year end change.

 VXRTのテクニカル分析


 VXRTのニュース

   Vaxart Up on Pre-Clinical Data on Coronavirus Vaccine Candidates  2020/04/22 15:19:00 Zacks Investment Research
Vaxart's (VXRT) several COVID-19 vaccine candidates generate immune responses in pre-clinical studies. Stock rises.
   Pre-Market: Vaxart Pops 35% On Positive Covid-19 Vaccine Data  2020/04/21 13:03:05 Smarter Analyst
Biotech Vaxart (VXRT) has announced positive pre-clinical results for its oral COVID-19 vaccine candidates, with several of the vaccine candidates generating immune responses … The post Pre-Market: Vaxart Pops 35% On Positive Covid-19 Vaccine Data appeared first on Smarter Analyst .
   10 Biotech Winners And Losers In Q1  2020/04/01 20:35:44 Benzinga
The quarter was brutal to say the least for most asset classes amid the coronavirus (COVID-19) pandemic. The S&P 500 Index was down about 20% for the quarter. Amid the market mayhem, some health care stocks defied the downturn, thanks to announcements concerning development of drug/vaccine/diagnostic tests for new coronavirus. Focusing on biotechs (leaving out diagnostics stocks), here the top five winners and losers for the quarter. Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter . The Winners Genprex Inc (NASDAQ: GNPX ): (+656.25%) After ending 2019 in penny stock territory, shares of this gene therapy company began to gain ground after the company announced Fast Track Designation for its immunogene therapy in combination with AstraZeneca's (NYSE: AZN ) Tagrisso for treating lung cancer. The momentum accelerated after it signed an exclusive agreement to license a diabetes gene therapy from the University of Pittsburgh.
   Vaxart, Emergent Biosolutions Partner On Coronavirus Vaccine Development  2020/03/18 15:48:28 Benzinga
Vaxart Inc (NASDAQ: VXRT ) shares were advancing Wednesday following an update from the company on its COVID-19 vaccine program. Vaxart said it has entered into an agreement with Emergent Biosolutions Inc (NYSE: EBS ) that will allow Emergent to deploy its molecule-to-market contract development and manufacturing services to develop and manufacture Vaxart's oral vaccine candidate for COVID-19. The oral recombinant vaccine candidate is based on Vaxart's proprietary VAAST platform, according to the company. Benzinga is covering every … Full story available on Benzinga.com
   A Vaccine for Coronavirus? These 3 Healthcare Stocks Are Working on It  2020/02/12 14:30:07 Nasdaq
Fear and uncertainty have gripped the global population as the number of confirmed coronavirus cases grows daily. What started in Wuhan, the capital of China’s Hubei province, has now spread to 43,101 people in 25 different countries, according to the World Health Organization (WHO), killing over 1,000. While 75% of the infections have occurred in the Hubei province, a worldwide effort to contain the virus, now deemed as COVID-19 by WHO, is underway. These efforts include a two-day forum to create a “global research agenda” as well as quarantining individuals returning from the virus’ epicenter for 14 days, with the first 195 U.S. citizens under quarantine being released on February 11. The Centers for Disease Control and Prevention (CDC) has confirmed that 13 people in the U.S. have been infected, with the most recent case in San Diego after a repatriated individual that originally tested negative for the virus developed symptoms. As so much about COVID-19 remains unknown, it has become a race against the clock to find solutions.
   Vaxart, Emergent Biosolutions Partner On Coronavirus Vaccine Development  2020/03/18 15:48:28 Benzinga
Vaxart Inc (NASDAQ: VXRT ) shares were advancing Wednesday following an update from the company on its COVID-19 vaccine program. Vaxart said it has entered into an agreement with Emergent Biosolutions Inc (NYSE: EBS ) that will allow Emergent to deploy its molecule-to-market contract development and manufacturing services to develop and manufacture Vaxart's oral vaccine candidate for COVID-19. The oral recombinant vaccine candidate is based on Vaxart's proprietary VAAST platform, according to the company. Benzinga is covering every … Full story available on Benzinga.com
   A Vaccine for Coronavirus? These 3 Healthcare Stocks Are Working on It  2020/02/12 14:30:07 Nasdaq
Fear and uncertainty have gripped the global population as the number of confirmed coronavirus cases grows daily. What started in Wuhan, the capital of China’s Hubei province, has now spread to 43,101 people in 25 different countries, according to the World Health Organization (WHO), killing over 1,000. While 75% of the infections have occurred in the Hubei province, a worldwide effort to contain the virus, now deemed as COVID-19 by WHO, is underway. These efforts include a two-day forum to create a “global research agenda” as well as quarantining individuals returning from the virus’ epicenter for 14 days, with the first 195 U.S. citizens under quarantine being released on February 11. The Centers for Disease Control and Prevention (CDC) has confirmed that 13 people in the U.S. have been infected, with the most recent case in San Diego after a repatriated individual that originally tested negative for the virus developed symptoms. As so much about COVID-19 remains unknown, it has become a race against the clock to find solutions.
   Vaxart (VXRT) to Make Vaccines to Check Coronavirus, Stock Up  2020/02/03 10:16:00 Zacks Investment Research
Vaxart (VXRT) begins a program to develop a vaccine candidate to counter the new coronavirus infection. Shares jump.
   Vaxart's stock rockets on heavy volume after initiating coronavirus vaccine development program  2020/01/31 19:08:00 MarketWatch
Shares of Vaxart Inc. rocketed 54% on heavy volume in afternoon trading, putting them on track for the first close above the $1 mark in nearly 10 months,…
   Zacks: Vaxart Inc (NASDAQ:VXRT) Given Consensus Rating of “Strong Buy” by Brokerages  2019/11/12 22:38:47 Modern Readers
Vaxart Inc (NASDAQ:VXRT) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the stock, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy rating. Brokers have set a 12-month consensus target price of $4.00 for the company and are […]
   A Vaccine for Coronavirus? These 3 Healthcare Stocks Are Working on It  2020/02/12 14:30:07 Nasdaq
Fear and uncertainty have gripped the global population as the number of confirmed coronavirus cases grows daily. What started in Wuhan, the capital of China’s Hubei province, has now spread to 43,101 people in 25 different countries, according to the World Health Organization (WHO), killing over 1,000. While 75% of the infections have occurred in the Hubei province, a worldwide effort to contain the virus, now deemed as COVID-19 by WHO, is underway. These efforts include a two-day forum to create a “global research agenda” as well as quarantining individuals returning from the virus’ epicenter for 14 days, with the first 195 U.S. citizens under quarantine being released on February 11. The Centers for Disease Control and Prevention (CDC) has confirmed that 13 people in the U.S. have been infected, with the most recent case in San Diego after a repatriated individual that originally tested negative for the virus developed symptoms. As so much about COVID-19 remains unknown, it has become a race against the clock to find solutions.
   Vaxart (VXRT) to Make Vaccines to Check Coronavirus, Stock Up  2020/02/03 10:16:00 Zacks Investment Research
Vaxart (VXRT) begins a program to develop a vaccine candidate to counter the new coronavirus infection. Shares jump.
   Vaxart's stock rockets on heavy volume after initiating coronavirus vaccine development program  2020/01/31 19:08:00 MarketWatch
Shares of Vaxart Inc. rocketed 54% on heavy volume in afternoon trading, putting them on track for the first close above the $1 mark in nearly 10 months,…
   Zacks: Vaxart Inc (NASDAQ:VXRT) Given Consensus Rating of “Strong Buy” by Brokerages  2019/11/12 22:38:47 Modern Readers
Vaxart Inc (NASDAQ:VXRT) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the stock, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy rating. Brokers have set a 12-month consensus target price of $4.00 for the company and are […]
   Armistice Capital Master Fund Purchases 200,000 Shares of Vaxart Inc (NASDAQ:VXRT) Stock  2019/11/12 09:33:54 Modern Readers
Vaxart Inc (NASDAQ:VXRT) major shareholder Armistice Capital Master Fund acquired 200,000 shares of the company’s stock in a transaction that occurred on Thursday, November 7th. The stock was bought at an average cost of $0.35 per share, with a total value of $70,000.00. Major shareholders that own 10% or more of a company’s stock are […]

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アビラジェン・セラピュ―ティクス VXRT Vaxart Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)